FENC - NASDAQ
Fennec Pharmaceuticals Inc.
$9.35
-6.3%Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
At a Glance
Live SnapshotNo Investing Cash Flow Data
FENC has not reported any investing cash flow values in the available annual periods.
Fennec Pharmaceuticals Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Fennec Pharmaceuticals Inc. Cash Flow Statement
FENC • NASDAQ
| Fennec Pharmaceuticals Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-10.3M | -436K | -16M | -23.7M | -17.3M | -18.1M | -12.8M | -9.9M | -7M | -2.8M | -659K | -2.2M | 1.8M | -5.2M | 4.7M | -7.8M | -3M | -13.6M | -13.4M | -19.1M | |
103K | 959K | 287K | 149K | 16K | 0.0 | 64K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 164K | 192K | 2.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -64K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.5M | |
7M | 5.1M | 5.4M | 4.2M | 4M | 2.8M | 3.1M | 1.8M | 1.5M | 615K | 97K | 627K | 87K | 326K | 250K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
5.8M | 28.7M | 1.4M | 1.8M | -769K | 386K | 481K | 105K | 875K | 40K | -1.2M | -270K | -3.8M | 1.6M | -8.1M | 5.8M | 213K | 2.5M | 2.3M | 2.6M | |
-15.1M | -7.3M | -8.2M | -509K | -138K | -663K | 569K | 132K | 1M | 10K | -63K | 120K | -365K | 280K | -81K | 116K | -1.9M | 134K | -2.5M | 2.1M | |
-12.5M | 27M | -17.1M | -18.1M | -14.2M | -15.6M | -9.1M | -7.8M | -3.6M | -2.1M | -1.9M | -1.7M | -2.2M | -3M | -3.2M | -1.9M | -4.7M | -10.8M | -13.3M | -13.5M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -15K | -73K | -5K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 24K | -15K | -2K | 1.2M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (24K) | -15K | -75K | (1.2M) | |
FINANCING ACTIVITIES | ||||||||||||||||||||
45M | -176K | -78K | -194K | 0.0 | 32M | 0.0 | 0.0 | 27.4M | 5M | 0.0 | 2.2M | 1.6M | 0.0 | 2.6M | 7.2M | 0.0 | 0.0 | 23.9M | 6.1M | |
-19.8M | -13M | 5M | 20.2M | 5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -40K | 28K | |
(0.0) | -176K | -78K | -194K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-2.6M | -439K | 1.7M | 753K | -8K | 322K | -71K | 2.3M | 594K | 108K | 497K | 161K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7K | 0.0 | -70K | |
22.6M | -13.6M | 6.6M | 20.7M | 5M | 32.3M | -71K | 2.3M | 28M | 5.1M | 497K | 2.3M | 1.6M | 0.0 | 2.6M | 7.2M | 0.0 | 7K | 23.9M | 6.1M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10K | 0.0 | 0.0 | 3K | 0.0 | 0.0 | |
10.2M | 13.4M | -10.5M | 2.7M | -9.2M | 16.7M | -9.1M | -5.5M | 24.3M | 3M | -1.4M | 644K | -640K | -3M | -650K | 5.3M | -4.7M | -10.8M | 10.5M | -6.3M | |
26.6M | 13.3M | 23.8M | 21.1M | 30.3M | 13.7M | 22.8M | 28.3M | 3.9M | 942K | 2.3M | 1.7M | 2.3M | 5.3M | 5.9M | 685K | 5.3M | 16.2M | 5.7M | 11.9M | |
36.8M | 26.6M | 13.3M | 23.8M | 21.1M | 30.3M | 13.7M | 22.8M | 28.3M | 3.9M | 942K | 2.3M | 1.7M | 2.3M | 5.3M | 5.9M | 685K | 5.3M | 16.2M | 5.7M | |
-12.5M | 27M | -17.1M | -18.1M | -14.2M | -15.6M | -9.1M | -7.8M | -3.6M | -2.1M | -1.9M | -1.7M | -2.2M | -3M | -3.2M | -1.9M | -4.7M | -10.8M | -13.4M | -13.5M |
SEC Filings
FENC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 07, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 |
Related Guides
Continue your FENC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.